Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|October 20, 2021
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancerYue Zeng, Danlei Yu, Wentao Tian, et al.
Acta Biomaterialia|May 28, 2021
Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancerWu Chen, Danlei Yu, Shi-Yong Sun, et al.
Neoplasia (New York, N.Y.)|May 16, 2023
ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppressionWen Zhao, Danlei Yu, Yifan Zhai, et al.
Lung Cancer (Auckland, N.Z.)|February 12, 2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK SignalingDanlei Yu, Wen Zhao, Karin A Vallega, et al.
Nursing Open|April 11, 2026
The Mediating Effect of Teamwork Attitude Between Cultural Intelligence and Teamwork Cognition in Nursing StudentsYanfen Gu, Yili Gao, Lin Zhou, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 5, 2025
A Compact Dead-Zone-Free Multi-Channel Stimulation and Recording System for Precision Peripheral Nerve ModulationYanjie Xing, Weihuang Chen, Danlei Yu, et al.
Translational Cancer Research|May 25, 2026
A novel risk model of cholesterol metabolism-related mRNAs for predicting overall survival and immune signature in glioma based on machine learning and multi-omics dataDanlei Yu, Kecheng Shen, Jun Wang, et al.
Oncogene|October 12, 2021
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinibZhen Chen, Danlei Yu, Taofeek K Owonikoko, et al.
Open Medicine (Warsaw, Poland)|October 3, 2023
Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genesHaijun Guo, Yunqing Zhi, Kaijing Wang, et al.
Cancer Letters|July 10, 2021
Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosisWen Zhao, Danlei Yu, Zhen Chen, et al.
Pageof 2